SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Nymann T, Shokouh-Amiri MH, Vera SR, Riely CA, Alloway RR, Gaber AO. Prevention of hepatitis B recurrence with indefinite hepatitis B immune globulin (HBIG) prophylaxis after liver transplantation. Clin Transplant. 1996; 10: 663667.
  • 2
    Sawyer RG, McGory RW, Gaffey MJ, McCullough CC, Shephard BL, Houlgrave CW, et al. Improved clinical outcomes with liver transplantation for hepatitis B–induced chronic liver failure using passive immunization. Ann Surg. 1998; 227: 841850.
  • 3
    Terrault NA, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology. 1996; 24: 13271333.
  • 4
    Gish RG, Lau JY, Brooks L, Fang JW, Steady SL, Imperial JC, et al. Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients. Hepatology. 1996; 23: 17.
  • 5
    Gish RG, Keeffe EB, Lim J, Brooks LJ, Esquivel CO. Survival after liver transplantation for chronic hepatitis B using reduced immunosuppression. J Hepatol. 1995; 22: 257262.
  • 6
    Lake JR. Changing indications for liver transplantation. Gastroenterol Clin North Am. 1993; 22: 213229.
  • 7
    Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med. 1993; 329: 18421847.
  • 8
    Samuel D, Bismuth H. Liver transplantation for hepatitis B. Gastroenterol Clin North Am. 1993; 22: 271283.
  • 9
    Pruett TL, McGory R. Hepatitis B immune globulin: the US experience. Clin Transplant. 2000; 14(suppl 2): 713.
  • 10
    Wai CT, Fontana RJ, Polson J, Hussain M, Shakil AO, Han SH, et al. Clinical outcome and virological characteristics of hepatitis B–related acute liver failure in the United States. J Viral Hepat. 2005; 12: 192198.
  • 11
    Lo CM, Cheung CK, Lau GK, Yuen MF, Liu CL, Chan SC, et al. Significance of hepatitis B virus genotype in liver transplantation for chronic hepatitis B. Am J Transplant. 2005; 5: 18931900.
  • 12
    Schiff ER, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology. 2003; 38: 14191427.
  • 13
    Perrillo RP. Management of the patient with hepatitis B virus–related cirrhosis. J Hepatol. 2003; 39(suppl 1): S177S180.
  • 14
    Barcena R, Dominguez-Antonaya M, Lopez-Sanroman A, Martinez-Turnes A, Urman J, del Campo S, et al. Lamivudine therapy of hepatitis B virus–related liver disease: cirrhosis, posttransplantation recurrence, and de novo infection. Transplant Proc. 1999; 31: 24572458.
  • 15
    Fontana RJ, Lok AS. Lamivudine treatment in patients with decompensated hepatitis B cirrhosis: for whom and when? J Hepatol. 2000; 33: 329332.
  • 16
    Johnson MA, Horak J, Breuel P. The pharmacokinetics of lamivudine in patients with impaired hepatic function. Eur J Clin Pharmacol. 1998; 54: 363366.
  • 17
    Kapoor D, Guptan RC, Wakil SM, Kazim SN, Kaul R, Agarwal SR, et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol. 2000; 33: 308312.
  • 18
    Keeffe EB. End-stage liver disease and liver transplantation: role of lamivudine therapy in patients with chronic hepatitis B. J Med Virol. 2000; 61: 403408.
  • 19
    Leung N. Liver disease-significant improvement with lamivudine. J Med Virol. 2000; 61: 380385.
  • 20
    Van Thiel DH, Friedlander L, Kania RJ, Molloy PJ, Hassanein T, Wahlstrom E, et al. Lamivudine treatment of advanced and decompensated liver disease due to hepatitis B. Hepatogastroenterology. 1997; 44: 808812.
  • 21
    Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology. 2000; 31: 207210.
  • 22
    Zavaglia C, Airoldi A, Pinzello G. Antiviral therapy of HBV- and HCV-induced liver cirrhosis. J Clin Gastroenterol. 2000; 30: 234241.
  • 23
    Kitay-Cohen Y, Ben Ari Z, Tur-Kaspa R, Fainguelernt H, Lishner M. Extension of transplantation free time by lamivudine in patients with hepatitis B–induced decompensated cirrhosis. Transplantation. 2000; 69: 23822383.
  • 24
    Lau G, Cooksley H, Ribeiro RM, Powers KA, Bowden S, Mommeja-Marin H, et al. Randomized, double-blind study comparing adefovir dipivoxil (ADV) plus emtricitabine (FTC) combination therapy vs ADV alone in HBeAg(+) chronic hepatitis B: efficacy and mechanisms of treatment response. Hepatology. 2004; 40: 272A.
  • 25
    Lo CM, Liu CL, Lau GK, Chan SC, Ng IO, Fan ST. Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transpl. 2005; 11: 807813.
  • 26
    Neff GW, Zacharias VC, Alonzo M, Kemmer N, Weber F, Kaiser TE, et al. Conversion of liver transplant recipients with hepatitis B virus from hepatitis B immune globulin (HBIG) and lamivudine (LAM) to adefovir dipivoxil (ADV) and LAM. 41st Annual Meeting of the European Association for the Study of the Liver, April 26, 2006, Vienna, Austria.
  • 27
    Lim SG, Krastev Z, Ng TM, Mechkov G, Kotzev IA, Chan S, et al. Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B. Antimicrob Agents Chemother. 2006; 50: 16421648.
  • 28
    Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005; 129: 528536.
  • 29
    Locarnini S, Hatzakis A, Heathcote J, Keeffe EB, Liang TJ, Mutimer D, et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther. 2004; 9: 679693.
  • 30
    Lok AS, Fung SK, Han SH. Virological response and resistance to adefovir therapy in liver transplant patients. Hepatology. 2005; 42: 232A.
  • 31
    Lampertico P, Viganò M, Manenti E, Del Ninno E, Colombo M. No evidence for ADV resistance in HBeAg-negative lamivudine resistant patients treated with lamivudine-adefovir combination for 3 years [abstract 499]. 41st Annual Meeting of the European Association for the Study of the Liver, April 26–30, 2006, Vienna, Austria.
  • 32
    Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006; 354: 10011010.
  • 33
    Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006; 354: 10111020.
  • 34
    Gish RG, Chang TT, De Man RA, Gadano A, Sollano J, Han KH, et al. Entecavir results in substantial virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in HBeAg(+) chronic hepatitis B patients. Hepatology. 2005; 42: 267A.
  • 35
    Yurdaydin C, Senturk H, Boron-Kaczmarska A, Raptopoulou-Gigi M, Batur Y, Goodman Z, et al. Entecavir (ETV) demonstrates consistent responses throughout baseline disease and demographic subgroups for the treatment of lamivudine-refractory HBeAg(+) patients with chronic hepatitis B [abstract 512]. 41st Annual Meeting of the European Association for the Study of the Liver, Vienna, Austria, April 26–30, 2006.
  • 36
    Yurdaydin C, Sollano J, Hadziyannis S, Kaymakoglu S, Sherman M, Brett-Smith H, et al. Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026) [abstract 80]. 41st Annual Meeting of the European Association for the Study of the Liver, Vienna, Austria, April 26–30, 2006.
  • 37
    Chang TT, Gish RG, Hadziyannis SJ, Cianciara J, Rizzetto M, Schiff ER, et al. A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology. 2005; 129: 11981209.
  • 38
    Akarca U, Hatzis G, Kitis G, Shouval D, Lai C, Cheinquer H, et al. Entecavir (ETV) treatment through 96 weeks results in virological and biochemical improvement in HBeAg(−) chronic hepatitis B patients (study ETV-027). Liver International 2006; 26(s1): 19.
  • 39
    Barcena R, del Campo S, Moraleda G, Casanovas T, Prieto M, Buti M, et al. Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virus. Transplant Proc. 2005; 37: 39603962.
  • 40
    Gornals JB, Casanovas T, Sabido M, Baliellas C, Casanovas A, Canas C, et al. Clinical and virological effects during two years of ongoing adefovir dipivoxil in the treatment of lamivudine-resistant chronic hepatitis B infection. Transplant Proc. 2005; 37: 39573959.
  • 41
    Herreros de Tejada EA, Moreno Planas JM, Rubio GE, Portero AF, Lopez MJ, Revilla NJ, et al. Adefovir dipivoxil therapy in liver transplant recipients with lamivudine-resistant hepatitis B virus. Transplant Proc. 2005; 37: 15071508.
  • 42
    Marzano A, Lampertico P, Mazzaferro V, Carenzi S, Vigano M, Romito R, et al. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transpl. 2005; 11: 532538.
  • 43
    Beckebaum S, Malago M, Dirsch O, Cicinnati VR, Trippler M, Lampertico P, et al. Efficacy of combined lamivudine and adefovir dipivoxil treatment for severe HBV graft reinfection after living donor liver transplantation. Clin Transplant. 2003; 17: 554559.
  • 44
    Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology. 2000; 32: 129134.
  • 45
    Chan HL, Chui AK, Lau WY, Chan FK, Hui AY, Rao AR, et al. Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monoprophylaxis. Clin Transplant. 2004; 18: 295300.
  • 46
    Peters MG, Hann HH, Martin P, Heathcote EJ, Buggisch P, Rubin R, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2004; 126: 91101.
  • 47
    Wilber R, Brett-Smith H., Zhu J, Mencarini K, Colonno R., Cross A, Lopez-Talavera, J. C. Entecavir (ETV) vs. adefovir (ADV): HBV DNA reduction in chronically infected HBeAg(+) nucleoside-naive adults in a 12-week viral kinetics study. NIH Management of Hepatitis B Conference, Bethesda, MD, April 6, 2006.
  • 48
    Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother. 2004; 48: 34983507.
  • 49
    Taltavull TC, Chahri N, Verdura B, Gornals J, Lopez C, Casanova A, et al. Successful treatment with tenofovir in a child C cirrhotic patient with lamivudine-resistant hepatitis B virus awaiting liver transplantation: post-transplant results. Transpl Int. 2005; 18: 879883.
  • 50
    Neff GW, O'Brien CB, Nery J, Shire N, Montalbano M, Ruiz P, et al. Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. Liver Transpl. 2004; 10: 13721378.
  • 51
    Samuel D, Bismuth H, Benhamou JP. Liver transplantation in cirrhosis due to hepatitis D virus infection. J Hepatol. 1993; 17(suppl 3): S154S156.
  • 52
    McGory R. Pharmacoeconomic analysis of HBV liver transplant therapies. Clin Transplant. 2000; 14(suppl 2): 2938.
  • 53
    Lucey MR, Graham DM, Martin P, Di Bisceglie A, Rosenthal S, Waggoner JG, et al. Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation. Gut. 1992; 33: 13901396.
  • 54
    Ottobrelli A, Marzano A, Smedile A, Recchia S, Salizzoni M, Cornu C, et al. Patterns of hepatitis delta virus reinfection and disease in liver transplantation. Gastroenterology. 1991; 101: 16491655.
  • 55
    Terrault NA, Zhou S, McCory RW, Pruett TL, Lake JR, Roberts JP, et al. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology. 1998; 28: 555561.
  • 56
    Dodson SF, de Vera ME, Bonham CA, Geller DA, Rakela J, Fung JJ. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl. 2000; 6: 434439.
  • 57
    Nath DS, Kalis A, Nelson S, Payne WD, Lake JR, Humar A. Hepatitis B prophylaxis post-liver transplant without maintenance hepatitis B immunoglobulin therapy. Clin Transplant. 2006; 20: 206210.
  • 58
    Yao FY, Osorio RW, Roberts JP, Poordad FF, Briceno MN, Garcia-Kennedy R, et al. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg. 1999; 5: 49196.
  • 59
    Yoshida EM, Sherlock CH. Assessing virologic efficacy of combination lamivudine and low-dose hepatitis B immune globulin posttransplantation with the ultrasensitive digene hybrid capture II assay [letter]. Liver Transpl. 2000; 6: 386.
  • 60
    Nery JR, Nery-Avila C, Berho M, Weppler D, Statler A, Schiff E, et al. Preliver transplant viremic status and the choice of anti-HBV regimens. Transplant Proc. 2001; 33: 14281429.
  • 61
    Ferretti G, Merli M, Ginanni CS, Callejon V, Tanzilli P, Masini A, et al. Low-dose intramuscular hepatitis B immune globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation. Transplant Proc. 2004; 36: 535538.
  • 62
    Villamil FG. Hepatitis B: progress in the last 15 years. Liver Transpl. 2002; 8: S59S66.
  • 63
    Dan YY, Wai CT, Yeoh KG, Lim SG. Prophylactic strategies for hepatitis B patients undergoing liver transplant: a cost-effectiveness analysis. Liver Transpl. 2006; 12: 736746.
  • 64
    Ghany MG, Ayola B, Villamil FG, Gish R, Vierling JM, Lok ASF. S gene escape mutants as a cause of HBV reinfection in patients who received HBIG post-OLT. Hepatology. 1995; 22: 150A.
  • 65
    Carman WF, Owsianka A, Wallace LA, Dow BC, Mutimer DJ. Antigenic characterization of pre- and post-liver transplant hepatitis B surface antigen sequences from patients treated with hepatitis B immune globulin. J Hepatol. 1999; 31: 195201.
  • 66
    Shields PL, Owsianka A, Carman WF, Boxall E, Hubscher SG, Shaw J, et al. Selection of hepatitis B surface “escape” mutants during passive immune prophylaxis following liver transplantation: potential impact of genetic changes on polymerase protein function. Gut. 1999; 45: 306309.
  • 67
    Carman WF, Trautwein C, van Deursen FJ, Colman K, Dornan E, McIntyre G, et al. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology. 1996; 24: 489493.
  • 68
    Germer JJ, Charlton MR, Ishitani MB, Forehand CD, Patel R. Characterization of hepatitis B virus surface antigen and polymerase mutations in liver transplant recipients pre- and post-transplant. Am J Transplant. 2003; 3: 743753.
  • 69
    Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, et al. A multicenter United States–Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology. 2001; 33: 424432.
  • 70
    Perrillo RP, Schiff ER, Dienstag JL, Gish RG, Dickson RC, Adams PC, et al. Lamivudine for prevention of recurrent hepatitis B after liver transplantation: final results of a US/Canadian multicenter trial. Hepatology. 1999; 3: A245.
  • 71
    Fontana RJ, Hann HW, Wright T, Everson G, Baker A, Schiff ER, et al. A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. Liver Transpl. 2001; 7: 504510.
  • 72
    Mutimer D, Dusheiko G, Barrett C, Grellier L, Ahmed M, Anschuetz G, et al. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up. Transplantation. 2000; 70: 809815.
  • 73
    Angus P, Richards M, Bowden S, Ireton J, Sinclair R, Jones R, et al. Combination antiviral therapy controls severe post-liver transplant recurrence of hepatitis B virus infection. J Gastroenterol Hepatol. 1993; 8: 353357.
  • 74
    Ben Ari Z, Mor E, Shapira Z, Tur-Kaspa R. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation. Liver Transpl. 2001; 7: 113117.
  • 75
    Boker KH, Ringe B, Krüger M, Pichlmayr R, Manns MP. Prostaglandin E plus famciclovir—a new concept for the treatment of severe hepatitis B after liver transplantation. Transplantation. 1994; 57: 17061708.
  • 76
    Broomë U, Glaumann H, Hellers G, Nilsson B, Sörstad J, Hultcrantz R. Liver disease in ulcerative colitis: an epidemiological and follow up study in the county of Stockholm. Gut. 1994; 35: 8489.
  • 77
    Klein M, Geoghegan J, Schmidt K, Bockler D, Korn K, Wittekind C, et al. Conversion of recurrent delta-positive hepatitis B infection to seronegativity with famciclovir after liver transplantation. Transplantation. 1997; 64: 162163.
  • 78
    Petry W, Adams O, Haussinger D. Fatal hepatitis B reinfection after orthotopic liver transplantation in an HBsAg negative patient following withdrawal of lamivudine. J Hepatol. 2000; 33: 514515.
  • 79
    Zheng S, Chen Y, Liang T, Lu A, Wang W, Shen Y, et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B immunoglobulin prophylaxis. Liver Transpl. 2006; 12: 253258.
  • 80
    Yeon JE, Yoo W, Hong SP, Chang YJ, Yu SK, Kim JH, et al. Resistance to adefovir dipivoxil (ADV) in lamivudine- resistant chronic hepatitis B patients treated with ADV. Gut. 2006; 55: 14881495.
  • 81
    Gutfreund KS, Williams M, George R, Bain VG, Ma MM, Yoshida EM, et al. Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance. J Hepatol. 2000; 33: 469475.
  • 82
    Naoumov NV, Lopes AR, Burra P, Caccamo L, Iemmolo RM, De Man RA, et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol. 2001; 34: 888894.
  • 83
    Malkan G, Cattral MS, Humar A, Al Asghar H, Greig PD, Hemming AW, et al. Lamivudine for hepatitis B in liver transplantation: a single-center experience. Transplantation. 2000; 69: 14031407.
  • 84
    Schiff ER. Lamivudine for hepatitis B in clinical practice. J Med Virol. 2000; 61: 386391.
  • 85
    Yoshida EM, Ma MM, Davis JE, Fischer KP, Kneteman NM, Erb SR, et al. Postliver transplant allograft reinfection with a lamivudine-resistant strain of hepatitis B virus: long-term follow-up. Can J Gastroenterol. 1998; 12: 125129.
  • 86
    Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet. 1997; 349: 2022.
  • 87
    Aye TT, Bartholomeusz A, Shaw T, Bowden S, Breschkin A, McMillan J, et al. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol. 1997; 26: 11481153.
  • 88
    De Man RA, Bartholomeusz AI, Niesters HG, Zondervan PE, Locarnini SA. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. J Hepatol. 1998; 29: 669675.
  • 89
    McCaughan GW, Spencer J, Koorey D, Bowden S, Bartholomeusz A, Littlejohn M, et al. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. Liver Transpl Surg. 1999; 5: 512519.
  • 90
    Ben Ari Z, Pappo O, Zemel R, Mor E, Tur-Kaspa R. Association of lamivudine resistance in recurrent hepatitis B after liver transplantation with advanced hepatic fibrosis. Transplantation. 1999; 68: 232236.
  • 91
    Mutimer D, Pillay D, Shields P, Cane P, Ratcliffe D, Martin B, et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut. 2000; 46: 107113.
  • 92
    Caccamo L, Romeo R, Rossi G, Maggioni M, Radice F, Lunghi G, et al. No hepatitis recurrence using combination prophylaxis in HBV-positive liver transplant recipients with YMDD mutants. Transpl Int. 2005; 18: 186192.
  • 93
    McCaughan GW, O'Brien E, Sheil AG. A follow up of 53 adult patients alive beyond 2 years following liver transplantation. J Gastroenterol Hepatol. 1993; 8: 569573.
  • 94
    Cooksley WG, McIvor CA. Fibrosing cholestatic hepatitis and HBV after bone marrow transplantation. Biomed Pharmacother. 1995; 49: 117124.
  • 95
    Hung YB, Liang JT, Chu JS, Chen KM, Lee CS. Fulminant hepatic failure in a renal transplant recipient with positive hepatitis B surface antigens: a case report of fibrosing cholestatic hepatitis. Hepatogastroenterology. 1995; 42: 913918.
  • 96
    Kairaitis LK, Gottlieb T, George CR. Fatal hepatitis B virus infection with fibrosing cholestatic hepatitis following renal transplantation. Nephrol Dial Transplant. 1998; 13: 15711573.
  • 97
    McIvor C, Morton J, Bryant A, Cooksley WG, Durrant S, Walker N. Fatal reactivation of precore mutant hepatitis B virus associated with fibrosing cholestatic hepatitis after bone marrow transplantation. Ann Intern Med. 1994; 121: 274275.
  • 98
    Munoz DB, Ibarrola C, Andres A, Colina F, Morales JM. Hepatitis-B-virus-related fibrosing cholestatic hepatitis after renal transplantation with acute graft failure following interferon-alpha therapy. Nephrol Dial Transplant. 1998; 13: 15741576.
  • 99
    Angus PW, Locarnini SA, McCaughan GW, Jones RM, McMillan JS, Bowden DS. Hepatitis B virus precore mutant infection is associated with severe recurrent disease after liver transplantation. Hepatology. 1995; 21: 1418.
  • 100
    Jamal H, Regenstein F, Farr G, Perrillo RP. Prolonged survival in fibrosing cholestatic hepatitis with long-term ganciclovir therapy. Am J Gastroenterol. 1996; 91: 10271030.
  • 101
    Akay S, Karasu Z, Akyildiz M, Tokat Y. Adefovir treatment in posttransplant hepatitis B virus infection resistant to lamivudine plus hepatitis B virus immunoglobulin. Transplant Proc. 2004; 36: 27682770.
  • 102
    Kim WR, Wiesner RH, Poterucha JJ, Therneau TM, Malinchoc M, Benson JT, et al. Hepatic retransplantation in cholestatic liver disease: impact of the interval to retransplantation on survival and resource utilization. Hepatology. 1999; 30: 395400.
  • 103
    Crippin J, Foster B, Carlen S, Borcich A, Bodenheimer H Jr. Retransplantation in hepatitis B—a multicenter experience. Transplantation. 1994; 57: 823826.
  • 104
    Colina F, Mollejo M, Moreno E, Alberti N, Garcia I, Gomez-Sanz R, et al. Effectiveness of histopathological diagnoses in dysfunction of hepatic. Arch Pathol Lab Med. 1991; 115: 9981005.
  • 105
    Hassanein T, Colantoni A, De Maria N, Van Thiel DH. Interferon-alpha 2b improves short-term survival in patients transplanted for chronic liver failure caused by hepatitis B. J Viral Hepat. 1996; 3: 333340.
  • 106
    Rakela J, Wooten RS, Batts KP, Perkins JD, Taswell HF, Krom RA. Failure of interferon to prevent recurrent hepatitis B infection in hepatic allograft. Mayo Clin Proc. 1989; 64: 429432.
  • 107
    Gonzalez RA, de la MM, de la TJ, Mino G, Pera C, Pena J, et al. Levels of HBV-DNA and HBsAg after acute liver allograft rejection treatment by corticoids and OKT3. Clin Transplant. 2000; 14: 208211.
  • 108
    Matthew EB, Dietzman DE, Madden DL, Sever JL, al Aish MS, Dodson WE. Possible absence of Australia antigen in G-G translocation-type Down's syndrome. Lancet. 1971; 1: 702.
  • 109
    Behbehani AM. The hepatitis story. Search for a cause. J Kans Med Soc. 1971; 72: 227231.
  • 110
    McMaster P, Gunson B, Min X, Afonso R, Bastos J. Liver transplantation: changing goals in immunosuppression. Transplant Proc. 1998; 30: 18191821.
  • 111
    Szmuness W, Prince AM, Cherubin CE. Serum hepatitis antigen (SH) carrier state: relation to ABO blood groups. Br Med J. 1971; 2: 198199.
  • 112
    Caccamo L, Rossi G, Gridelli B, Maggi U, Reggiani P, Colledan M, et al. High-rate hepatitis and low-rate rejection induced late morbidity and mortality in long-term follow-up after liver transplantation. Transplant Proc. 1998; 30: 18281829.
  • 113
    Ingelman-Sundberg M, Johansson I, Yin H, Terelius Y, Eliasson E, Clot P, et al. Ethanol-inducible cytochrome P4502E1: genetic polymorphism, regulation, and possible role in the etiology of alcohol-induced liver disease. Alcohol. 1993; 10: 447452.
  • 114
    Yoshida H, Iwabuchi S, Murayama M, Uchikoshi T. [Long-term prognosis of the interferon-treated patients with chronic hepatitis C]. Nippon Rinsho. 1995; 53(suppl): 67579.
  • 115
    Ilan Y, Nagler A, Shouval D, Ackerstein A, Or R, Kapelushnik J, et al. Development of antibodies to hepatitis B virus surface antigen in bone marrow transplant recipient following treatment with peripheral blood lymphocytes from immunized donors. Clin Exp Immunol. 1994; 97: 299302.
  • 116
    Lau GK, Lok AS, Liang RH, Lai CL, Chiu EK, Lau YL, et al. Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer. Hepatology. 1997; 25: 14971501.
  • 117
    Lau GK, Wu PC, Liang R, Yuen ST, Lim WL. Persistence of hepatic hepatitis B virus after serological clearance of HBsAg with autologous peripheral stem cell transplantation. J Clin Pathol. 1997; 50: 706708.
  • 118
    Franchello A, Ghisetti V, Marzano A, Romagnoli R, Salizzoni M. Transplantation of hepatitis B surface antigen-positive livers into hepatitis B virus-positive recipients and the role of hepatitis delta coinfection. Liver Transpl. 2005; 11: 922928.
  • 119
    Guaraldi G, Cocchi S, Codeluppi M, Di Benedetto F, Bonora S, Pecorari M, et al. Role of therapeutic drug monitoring in a patient with human immunodeficiency virus infection and end-stage liver disease undergoing orthotopic liver transplantation. Transplant Proc. 2005; 37: 26092610.
  • 120
    Honkoop P, Kazemier G, Perenboom RM, van de Ende ME, De Man RA. [Liver transplantation in a HIV-positive patient receiving potent antiretroviral therapy; the first case in The Netherlands]. Ned Tijdschr Geneeskd. 2004; 148: 25002504.
  • 121
    Ristig M, Drechsler H, Crippin J, Lisker-Melman M, Tebas P. Management of chronic hepatitis B in an HIV-positive patient with 3TC-resistant hepatitis B virus. AIDS Patient Care STDS. 2003; 17: 439442.
  • 122
    Muller R, Wonigeit K, Bahlmann J, Schmidt FW, Pichlmayr R, Ostertag H, et al. [Significance of Australia antigen in patients after kidney transplantation]. Klin Wochenschr. 1971; 49: 768769.
  • 123
    Devlin J, Smith HM, O'Grady JG, Portmann B, Tan KC, Williams R. Impact of immunoprophylaxis and patient selection on outcome of transplantation for HBsAg-positive liver recipients. J Hepatol. 1994; 21: 204210.
  • 124
    Lerut JP, Donataccio M, Ciccarelli O, Roggen F, Jamart J, Laterre PF, et al. Liver transplantation and HBsAg-positive postnecrotic cirrhosis: adequate immunoprophylaxis and delta virus co-infection as the significant determinants of long-term prognosis. J Hepatol. 1999; 30: 706714.
  • 125
    Meinick JL, Boucher DW, Craske J, Boggs J. Properties of a virus isolated from patients with MS-1 infectious hepatitis. J Infect Dis. 1971; 124: 7685.
  • 126
    Funabashi S, Matsumoto Y, Shikage K, Kawai K. [Antibody for detection of Australia antigen]. Rinsho Byori. 1971; 19(suppl): 460.
  • 127
    Crespo J, Fabrega E, Casafont F, Rivero M, Heras G, de la Pena J, et al. Severe clinical course of de novo hepatitis B infection after liver transplantation. Liver Transpl Surg. 1999; 5: 175183.
  • 128
    Nery JR, Nery-Avila C, Reddy KR, Cirocco R, Weppler D, Levi DM, et al. Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. Transplantation. 2003; 75: 11791186.
  • 129
    Donataccio D, Roggen F, De Reyck C, Verbaandert C, Bodeus M, Lerut J. Use of anti-HBc positive allografts in adult liver transplantation: toward a safer way to expand the donor pool. Transpl Int. 2006; 19: 3843.
  • 130
    Hepatitis immunity. Br Med J. 1971; 3: 442443.
  • 131
    Heisto H, Julsrud AC, Ulstrup JC, Fagerhol MK. [Hepatitis associated antigen (HAA) and blood transfusion: a follow-up study of recipients of blood from donors with HAA and antibody]. Tidsskr Nor Laegeforen. 1971; 91: 15301531.
  • 132
    Kim CY, Bissell DM. Stability of the lipid and protein of hepatitis-associated (Australia) antigen. J Infect Dis. 1971; 123: 470476.
  • 133
    Marusawa H, Uemoto S, Hijikata M, Ueda Y, Tanaka K, Shimotohno K, et al. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology. 2000; 31: 488495.
  • 134
    Loss GE Jr, Mason AL, Nair S, Blazek J, Farr G, Guo L, et al. Does lamivudine prophylaxis eradicate persistent HBV DNA from allografts derived from anti-HBc–positive donors? Liver Transpl. 2003; 9: 12581264.
  • 135
    Karasu Z, Ozacar T, Akarca U, Ersoz G, Erensoy S, Gunsar F, et al. HBV vaccination in liver transplant recipients: not an effective strategy in the prophylaxis of HBV recurrence. J Viral Hepat. 2005; 12: 212215.
  • 136
    Barcena R, Fernandez-Braso M, Urman J, Lopez-San Roman A, del Campo S, Moreno N, et al. Response to hepatitis B virus vaccine in patients transplanted for HBV- related liver disease under specific gammaglobulin prophylaxis. Transplant Proc. 1999; 31: 24592460.
  • 137
    Sanchez-Fueyo A, Rimola A, Grande L, Costa J, Mas A, Navasa M, et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: a new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology. 2000; 31: 496501.
  • 138
    Weiss P. Safe vaccination against hepatitis B virus and discontinuation of hepatitis B immune globulin treatment in a liver transplanted patient. Transplant Proc. 2000; 32: 712713.